Comparing the effectiveness of testosterone-blocking medications in trans and gender diverse individuals

Phase 4

Completed

• Conditions: transgender; body composition; breast growth; Metabolic and Endocrine - Other endocrine disorders

• Registration Number: ACTRN12620000339954
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-11
• Study Completion: 2022-09-13
• Last Update Posted: 3 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Transgender individuals newly commencing feminising therapy with anti-androgen medication

Exclusion Criteria

Androgen deficiency at baseline
Planned orchidectomy within 6 months
Contraindication to treatment with estradiol, spironolactone or cyproterone (e.g. estrogen sensitive cancer, venous thromboembolic events, hyperkalaemia, severe depression)

Study & Design

• Study Type: Interventional
• Study Design: Not specified